FDA Nod For TSRO, D‚j… Vu For ARQL, FOMX Plunges On Trial Data, SELB Abuzz

The FDA has approved TESARO Inc.'s ZEJULA for the treatment of patients with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer. The drug is expected to be launched in the U.S. in late April.

from RTT - Biotech http://ift.tt/2oc3Do2
via IFTTT